ARWR Stock: Arrowhead Pharmaceuticals, Inc Reaches $5.00 After 3.00% Up Move

0
340

The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a huge mover today! The stock increased 13.64% or $0.6 during the last trading session, reaching $5. About 1.36M shares traded or 24.95% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since January 11, 2017 and is downtrending. It has underperformed by 83.97% the S&P500.The move comes after 5 months positive chart setup for the $374.14M company. It was reported on Jan, 11 by Barchart.com. We have $5.15 PT which if reached, will make NASDAQ:ARWR worth $11.22M more.

Webster Financial Corporation operates as the holding firm for Webster Bank, National Association that provides financial services to individuals, families, and businesses in the United States. The company has market cap of $5.79 billion. It operates through four divisions: Commercial Banking, Community Banking, HSA Bank, and Private Banking. It has a 23.02 P/E ratio. The Commercial Banking segment provides lending, deposit, and cash management services to middle market companies; and asset lending, commercial real estate, and equipment finance, as well as treasury and payment services, which include government and institutional banking.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $374.14 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Analysts await Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report earnings on February, 5. They expect $-0.15 earnings per share, up 11.76% or $0.02 from last year’s $-0.17 per share. After $-0.14 actual earnings per share reported by Arrowhead Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.14% negative EPS growth.

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Arrowhead Research Corp had 20 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, November 10, the company rating was maintained by Chardan Capital Markets. As per Monday, September 25, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Friday, August 19 by Cantor Fitzgerald. The firm has “Hold” rating given on Wednesday, August 5 by RBC Capital Markets. The rating was downgraded by PiperJaffray on Wednesday, November 30 to “Neutral”. The firm has “Neutral” rating given on Wednesday, November 30 by Piper Jaffray. On Monday, June 26 the stock rating was maintained by Jefferies with “Hold”. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Outperform” rating by William Blair on Monday, September 18. Jefferies maintained it with “Hold” rating and $200 target in Thursday, August 3 report. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Overweight” rating by PiperJaffray on Monday, November 27.

Analysts await Webster Financial Corporation (NYSE:WBS) to report earnings on January, 18. They expect $0.66 earnings per share, up 10.00% or $0.06 from last year’s $0.6 per share. WBS’s profit will be $65.40 million for 22.14 P/E if the $0.66 EPS becomes a reality. After $0.67 actual earnings per share reported by Webster Financial Corporation for the previous quarter, Wall Street now forecasts -1.49% negative EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 5 sales for $2.92 million activity.

Ratings analysis reveals 0 of Webster Financial’s analysts are positive. Out of 3 Wall Street analysts rating Webster Financial, 0 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. WBS was included in 3 notes of analysts from October 24, 2016. On Monday, October 24 the stock rating was maintained by FBR Capital with “Mkt Perform”. The stock of Webster Financial Corporation (NYSE:WBS) has “Market Perform” rating given on Monday, November 14 by Wells Fargo. The company was downgraded on Wednesday, November 16 by Piper Jaffray.

The stock increased 0.81% or $0.47 during the last trading session, reaching $58.46. About 119,447 shares traded. Webster Financial Corporation (WBS) has risen 33.32% since January 11, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Polaris Capital Management Llc holds 1.91% of its portfolio in Webster Financial Corporation for 648,741 shares. Penn Capital Management Co Inc owns 370,830 shares or 1.44% of their US portfolio. Moreover, Hood River Capital Management Llc has 1.25% invested in the company for 375,237 shares. The Connecticut-based Hartford Financial Management Inc. has invested 1.04% in the stock. Smith Graham & Co. Investment Advisors Lp, a Texas-based fund reported 182,690 shares.

LEAVE A REPLY

Please enter your comment!
Please enter your name here